Aptamer Sciences Inc
Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.
291650 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- South Korea
- Address:
- 경기도 성남시 분당구 판교로228번길 15 3동 301호(삼평동, 판교세븐벤처밸리1), 성남시
- Website:
- https://aptsci.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Aptamer Sciences Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative aptamer-based technologies for therapeutics and diagnostics. The company leverages its proprietary integrated platforms to address unmet medical needs, primarily in oncology. Its therapeutic pipeline is centered on the ApDC™ (Aptamer-Drug Conjugate) platform, with lead candidate AST-201 advancing to clinical trials for treating GPC3-positive solid tumors like liver cancer. In the diagnostics segment, the company has developed and commercialized the AptoDetect™ platform, which includes AptoDetect™-Lung, an aptamer-based diagnostic kit for assessing lung cancer risk. Aptamer Sciences focuses on advancing its pipeline and forming strategic partnerships to commercialize its novel aptamer technologies.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Aptamer Sciences Inc and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
Automate Your Workflow. Get a real-time feed of all Aptamer Sciences Inc filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Aptamer Sciences Inc via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
